“I'm not great at the advice. Can I interest you in a sarcastic comment?”

This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.

What is Ketamine infusion therapy?

Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.

Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.

However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.

Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”

Can Ketamine Infusion Therapy Kill Someone?

In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.

There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.

Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.

So, What Happened To Perry?

Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.

If it was not his session, then how did he get ketamine?

Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.

Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.

Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.

Who Are These Names And What Did They Do?

Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”

Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.

Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.

He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.

Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”

The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”

Dr Pepper, Bots, Cans

The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”

Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.

Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.

He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.

When I Die, I Want Helping Others To Be The First Thing That’s Mentioned

Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”

Five arrests have been made in the case so far.

The flu season has started earlier than expected in some parts of the country. The cases may erupt as soon as people start to travel, meet more people during the Thanksgiving and other upcoming holidays. However, there have been warning signs of a virus that has already set off massive outbreaks in UK and Canada, called the H3N2 subclade K.

What Is The Flu Strain Subclade K?

It is a variant of the H3N2 virus that had been circulating in other countries over the summers. Experts say the new variant is driving a surge in flu cases across Canada, Japan, and the U.K. Data from the Centers for Disease Control and Prevention shows that of nearly 150 test samples identified as part of the H3 lineage, more than half belonged to the subclade K group.

The influx of patients have been high too, as Dr Cameron Wolfe, a disease specialist at Duke University School of Medicine in Durham, North Carolina suggest, and is reported by the NBC. "At the moment, we’ve had two, three, four per day coming in," he said.

Alicia Budd, who leads the Centers for Disease Control and Prevention’s domestic influenza surveillance team, said flu activity in the United States is expected to rise steadily in the coming weeks.

How Dangerous Is The New H3N2 Flu Strain?

So far, most of the flu circulating this season is the H3N2 strain, which historically causes more hospitalizations and deaths among older adults. An early spike in cases, experts say, can heighten risks for this age group. Wolfe noted that when flu season begins unusually early, some nursing homes may still be rolling out vaccinations and some hospitals may not have fully vaccinated their staff. As a result, communities may be less protected than they typically would be if the virus peaked later in the winter.

Overall flu activity remains low, but the CDC’s latest report shows cases climbing. The agency estimates that at least 650,000 people have had the flu so far this season, with around 7,400 hospitalized and 300 deaths reported.

Budd said most of the rise in cases and emergency room visits is occurring in children. Last year, 280 children in the United States died from the flu, marking the deadliest pediatric flu season ever recorded outside the 2009 to 2010 H1N1 pandemic. No pediatric deaths have been reported yet this season, though doctors remain concerned after last winter’s rapid spread of the virus through schools, day care centers and hospitals.

“It feels like the calm before the storm,” said Dr. Buddy Creech, a pediatric infectious disease specialist at Vanderbilt University Medical Center. “We may have a difficult influenza year.”

H3N2 is known for mutating easily, and a new version of the strain, known as subclade K, appeared over the summer with several mutations. It emerged after this season’s flu shot formula had already been finalized and has already driven significant outbreaks in Canada and the United Kingdom.

Budd said the CDC is studying how well the current vaccine matches this evolving strain, but she urged people to get vaccinated regardless. Even when the circulating strain is not a perfect match, she said, the shot still helps reduce the severity of illness.

Doctors across the country are watching the latest trends closely. “Does it turn on our antenna a little bit more? Yes,” said Dr. Daniel Varga, chief physician executive at Hackensack Meridian Health in New Jersey. “It makes us even more vigilant about the monitoring we do locally.”

Dr. Melanie Kitagawa, medical director of the pediatric intensive care unit at Texas Children’s Hospital in Houston, stressed that it is not too late to get vaccinated. She said the more people who receive the flu shot before flu activity accelerates, the better protected communities will be.

Alzheimer’s patients have received discouraging news after the release of results from a major study. Novo Nordisk confirmed that its Alzheimer’s treatment did not show a “statistically significant” slowdown in the progression of the illness. Two trials evaluating the company’s weight loss medicine semaglutide in Alzheimer’s disease did not meet their targets, the firm said on Monday, as the drug failed to slow decline compared with a placebo.

Testing semaglutide, the active ingredient in Ozempic and Wegovy, for Alzheimer’s had always been viewed as a high-risk attempt, even though research has suggested the drug may influence several processes beyond metabolism. Still, Novo had raised interest in recent weeks by advertising roles connected to Alzheimer’s consumer marketing and medical affairs.

Novo Nordisk Says Alzheimer's Drug Trial Fails

Novo Nordisk said on Monday that an older oral form of semaglutide did not achieve its main outcome in late-stage trials assessing whether the drug could reduce cognitive decline in people with Alzheimer’s disease, sending its shares down by 10 percent.

The development dims expectations that Alzheimer’s could become a major new area for GLP-1 medicines like semaglutide, at a time when Novo is facing stronger competition for its leading products in obesity and diabetes. Treatment choices for Alzheimer’s patients remain limited. The company’s study had been closely followed as a potential sign of whether GLP-1 drugs, widely used for diabetes and weight control, might slow the condition’s advance.

The pill tested was Rybelsus, approved only for type 2 diabetes and containing semaglutide, as reported by Reuters.

Novo Nordisk: Lottery Ticket Fails

The firm’s Executive Vice President for Product and Portfolio Strategy, Ludovic Helfgott, had earlier described the Alzheimer’s trials as a “lottery ticket,” reflecting both the uncertainty and the considerable promise involved. Alzheimer’s and related dementias affect more than 55 million people worldwide, and no cure exists. “While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer’s disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities,” Chief Scientific Officer Martin Holst Lange said in a statement.

The findings from the two early-stage studies, EVOKE and EVOKE+, mark another setback for the Danish company and its new CEO Mike Doustdar. Novo had experienced remarkable success with Ozempic and Wegovy, but slower sales growth and a sharp drop in its stock value led to a leadership shift and significant job cuts.

The disappointment adds weight to analysts’ doubts about Novo’s Alzheimer’s plans, with UBS having earlier estimated only a 10 percent likelihood of success.

Novo Nordisk: Alzheimer’s Trial Stakes And Outcome

Alzheimer’s, marked by deep cognitive decline, fading memory and changes in behaviour, remains one of the hardest challenges in drug research. Novo had repeatedly acknowledged the uncertainty surrounding these studies. Even so, the possible payoff was significant. Analysts at Morgan Stanley had estimated that a breakthrough could have added up to $5 billion in yearly revenue.

“We believed it was important to assess whether semaglutide could offer any benefit,” Chief Scientific Officer Martin Holst Lange said, referring to the drug better known as Ozempic. The treatment did show improvement in certain biological markers connected to Alzheimer’s, but these gains did not lead to a slower progression of the condition.

Novo Nordisk Stock: Impact On Competition And Obesity Market

The company is also working to strengthen its footing in the obesity sector. Any sign that Wegovy could influence the most common form of dementia might have provided an edge over Eli Lilly’s Zepbound in the United States, where competition in this field is intensifying.

Delhi residents are once again dealing with heavy pollution as a dense layer of smog covered the city on November 22. In response to the worsening situation, the Commission for Air Quality Management (CAQM) on Saturday put GRAP Stage IV curbs into force, as several monitoring stations across the Capital recorded air in the ‘severe’ category.

Under the updated rules, the Government of National Capital Territory of Delhi and the NCR state administrations will decide whether public, municipal and private offices should function with only half their staff on site, with the remaining employees working from home. CAQM noted in its latest advisory, “CAQM has revised the GRAP schedule on 21.11.2025 to make it more stringent thus preventing further deterioration of air quality in Delhi-NCR.”

Which Measures Of GRAP 4 Are Being Taken Under GRAP 3?

As per CAQM, the following GRAP 4 steps will now be implemented during GRAP 3:

• NCR state governments and GNCTD will consider allowing public, municipal and private offices to operate at 50 percent capacity, with the remaining staff working remotely.
• The Central Government may also take a call on offering work-from-home options for employees in central government offices.

Other Restrictions In Delhi Under GRAP 3

Since GRAP 3 remains active in Delhi, activities such as non-essential construction, demolition work, and the use of older vehicle categories, including those below the Bharat Stage (BS)-IV emission norms, continue to be limited. People have been advised to minimise time spent outdoors, especially during the early mornings and late evenings when pollution is often at its peak. On Friday, the Delhi government also directed schools and other educational institutions to halt all sports and outdoor physical activities.

Stages of GRAP

GRAP follows four levels, each tied to the Air Quality Index (AQI) at the time.

Stage I of GRAP begins when air quality reaches the “poor” range (AQI between 201 and 300, which can cause breathing discomfort after prolonged exposure).

Stage II is enforced when air turns “very poor” (AQI between 301 and 400, which can result in respiratory issues with continued exposure).

Stage III comes into effect when pollution becomes “severe” (AQI between 401 and 500, a level at which even healthy individuals may feel the impact and those with existing conditions face serious health risks).

Stage IV of GRAP is declared when pollution crosses into the “severe+” range (AQI above 500).

India’s national AQI framework, created by the Central Pollution Control Board (CPCB), categorises air quality based on its potential impact on health, ranging from mild discomfort to significant respiratory and heart-related problems.

Each stage of GRAP includes a fixed set of actions for authorities to follow. As pollution increases and GRAP moves to the next stage, measures from earlier levels continue. This creates a step-by-step response system designed to slow down the rise in pollution and prevent conditions from becoming even more harmful.

At the moment, GRAP III is in force in Delhi, as air quality has been shifting between the ‘severe’ and ‘very poor’ bands. A range of restrictions linked to this stage is already being implemented across the city.